| pubmed-article:21042225 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21042225 | lifeskim:mentions | umls-concept:C0015967 | lld:lifeskim |
| pubmed-article:21042225 | lifeskim:mentions | umls-concept:C1332128 | lld:lifeskim |
| pubmed-article:21042225 | lifeskim:mentions | umls-concept:C0032743 | lld:lifeskim |
| pubmed-article:21042225 | lifeskim:mentions | umls-concept:C0281548 | lld:lifeskim |
| pubmed-article:21042225 | lifeskim:mentions | umls-concept:C1524063 | lld:lifeskim |
| pubmed-article:21042225 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:21042225 | pubmed:dateCreated | 2010-12-1 | lld:pubmed |
| pubmed-article:21042225 | pubmed:abstractText | Peritoneal carcinomatosis (PC) is associated with a very poor prognosis. Complete cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy has been shown to improve survival rates of PC. However, this treatment is beneficial for patients if the complete cytoreductive surgery is macroscopically completed before implementing hyperthermic intraperitoneal chemotherapy. Even so, a strict selection of patients is of fundamental importance because of the invasive nature of the intervention. The aim of this study was to assess the performance of FDG-PET/CT examinations for the diagnosis and evaluation of the extent of PC. | lld:pubmed |
| pubmed-article:21042225 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21042225 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21042225 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21042225 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21042225 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21042225 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21042225 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:21042225 | pubmed:issn | 1473-5628 | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:LorimierGérar... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:Le... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:MorelOlivierO | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:VerrièleVéron... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:BerthelotCéci... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:GiraultSylvie... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:PoirierAnne-L... | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:MorochJulienJ | lld:pubmed |
| pubmed-article:21042225 | pubmed:author | pubmed-author:BoucherYvanY | lld:pubmed |
| pubmed-article:21042225 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21042225 | pubmed:volume | 32 | lld:pubmed |
| pubmed-article:21042225 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21042225 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21042225 | pubmed:pagination | 23-9 | lld:pubmed |
| pubmed-article:21042225 | pubmed:dateRevised | 2011-5-20 | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:meshHeading | pubmed-meshheading:21042225... | lld:pubmed |
| pubmed-article:21042225 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21042225 | pubmed:articleTitle | Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy. | lld:pubmed |
| pubmed-article:21042225 | pubmed:affiliation | Department of aNuclear Medicine, University Hospital, Angers, France. | lld:pubmed |
| pubmed-article:21042225 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:21042225 | lld:pubmed |
